Results 111 to 120 of about 10,727,813 (262)

The smallest singular value anomaly: The reasons behind sharp anomaly

open access: yesSpecial Matrices
Let AA be an arbitrary matrix in which the number of rows, mm, is considerably larger than the number of columns, nn. Let the submatrix Ai,i=1,…,m{A}_{i},\hspace{0.33em}i=1,\ldots ,m, be composed from the first ii rows of AA, and let βi{\beta }_{i ...
Dax Achiya
doaj   +1 more source

IMPDH inhibition enhances cytarabine efficacy in SAMHD1‐expressing leukaemia cells via guanine nucleotide depletion

open access: yesMolecular Oncology, EarlyView.
Cytarabine is a key therapy for acute myeloid leukaemia (AML), but its efficacy is limited by the dNTPase SAMHD1, which hydrolyses its active metabolite. Screening nucleotide biosynthesis inhibitors revealed that IMPDH inhibitors selectively sensitise SAMHD1‐proficient AML cells to cytarabine.
Miriam Yagüe‐Capilla   +9 more
wiley   +1 more source

Il mito di Ulisse da Omero a Seneca

open access: yes, 2007
Il volume consiste nella traduzione e nel commento di venti testi antichi, greci e latini, da Omero a Luciano (compresi Pindaro e Properzio, Sofocle ed Euripide, Platone e Cicerone, Virgilio e Stazio, Ovidio e Seneca) che presentano diversi aspetti della
BETA, SIMONE
core   +1 more source

A handbook of the Beta of Wisconsin chapter, 1911-1923, Beloit College.

open access: yes, 1923
"Compiled by William Albert Hamilton, Secretary, Beta of Wisconsin."Mode of access ...
Phi Beta Kappa. Beta of Wisconsin (Beloit College)   +1 more
core  

KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer

open access: yesMolecular Oncology, EarlyView.
Treatment resistance is a major challenge for patients with advanced prostate cancer. This study examined an alternative approach to target the major prostate cancer‐promoting pathway by targeting epigenetic factors, whose levels are higher in tumours.
Jennie N Jeyapalan   +16 more
wiley   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

open access: yesMolecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary   +1 more
wiley   +1 more source

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

open access: yesMolecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska   +13 more
wiley   +1 more source

Lo spettacolo dei discorsi alla morte di Cesare: dal foro al teatro

open access: yes, 2011
L'articolo fa parte di un gruppo di quattro articoli riuniti sotto il titolo "Discorsi alla morte di Cesare: storiografia, oratoria, teatro"; gli altri autori sono Luigi Spina, Cristina Pepe e Andrea Balbo.
BETA, SIMONE
core   +1 more source

The Phi Beta Kappa Society Beta of Nebraska Chapter Constitution

open access: yes, 2012
Approved by the Chapter on September 24 ...
Phi Beta Kappa Society
core  

Loss of IGF‐1R impairs DNA‐PKcs recruitment to chromatin leading to defective end‐joining

open access: yesMolecular Oncology, EarlyView.
IGF‐1R promotes radioresistance by facilitating DNA‐PKcs recruitment to chromatin, enabling non‐homologous end‐joining (NHEJ) repair of double‐strand breaks. Inhibition or loss of IGF‐1R disrupts this recruitment to damage sites, driving compensatory reliance on microhomology‐mediated end‐joining (MMEJ) repair.
Matthew O. Ellis   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy